Business
MASIMO (NASDAQ: MASI) announced today the CE marking of SpHb ® , noninvasive and continuous hemoglobin monitoring, for neonatal and infant patients (< 3 kg).
With this clearance, the benefits of SpHb are available for patients of all ages in CE mark countries.
SpHb for neonates and infants is provided on rainbow ® sensors, which allow clinicians to simultaneously measure multiple additional noninvasive parameters alongside SpHb, including oxygen saturation (SpO 2 ) and methemoglobin (SpMet ® ).
Because of their small size, neonates and infants have less blood than older patients. In addition, their lack of bone marrow density makes them far less capable than adults of generating new red blood cells for approximately the first eight months of life.
Current invasive methodologies for measuring hemoglobin can only provide intermittent, delayed results. By providing a continuous, noninvasive measurement, SpHb allows clinicians to more closely monitor neonatal hemoglobin status in real time by tracking the stability, or instability, of a patient’s hemoglobin trend, providing visibility into changes, or lack of changes, in hemoglobin between invasive blood samples.
On adult patients, continuous monitoring with SpHb has been found to improve outcomes, such as reducing the percentage of patients receiving transfusions, reducing the units of red blood cells transfused per patient, reducing the time to transfusion, reducing costs and even reducing mortality 30 days after surgery.
In addition to hemoglobin, rainbow ® sensors monitor SpO 2 using Masimo SET ® Measure-through Motion and Low Perfusion™ technology, which has been shown in over 100 independent and objective studies to outperform other pulse oximetry technologies.
Crucially for newborn health, SET ® has been shown to help clinicians reduce severe retinopathy of prematurity in neonates and in multiple studies, including the largest critical congenital heart disease (CCHD) study to date, to improve CCHD screening in newborns.
The rainbow ® family of advanced noninvasive measurements also allows clinicians to use the same single sensor to monitor another physiological parameter particularly important to neonatal care: methemoglobin, using SpMet. SpMet helps clinicians noninvasively and continuously monitor methemoglobin levels in the blood.
In neonates and infants, inhaled nitric oxide (iNO) therapy and even topical anesthetics containing benzocaine or prilocaine can cause elevated levels of methemoglobin.
Joe Kiani, Founder and CEO of Masimo, said, “We are thrilled to be able to bring the power of noninvasive hemoglobin monitoring with SpHb to the youngest, most fragile patients of all.
“We have long been dedicated to helping improve the lives of neonatal and infant patients, and this latest clearance significantly furthers that mission. SpHb is already used to monitor adult patients in more than 75 countries. We look forward to witnessing the impact that SpHb will now be able to have on neonatal and infant patients.”
SpHb is not intended to replace laboratory blood testing. Clinical decisions regarding red blood cell transfusions should be based on the clinician’s judgment considering among other factors: patient condition, continuous SpHb monitoring, and laboratory diagnostic tests using blood samples.
Noninvasive, continuous SpHb has received FDA clearance for patients >3 kg but is not currently indicated for patients <3 kg in the US.
– Aug. 7, 2019 @ 10:25 GMT |
Tags: Continuous Hemoglobin Monitoring (SpHb ®) Masimo announces CE Marking of Neonatal Indication for Noninvasive
